Bioventus (BVS) Long-Term Deferred Tax (2021 - 2026)

Bioventus (BVS) has reported Long-Term Deferred Tax for 4 consecutive years, with $29.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax rose 512.27% year-over-year to $29.1 million; the trailing twelve-month figure through Jun 2026 stood at $29.1 million (up 512.27% YoY), and the FY2025 full-year result was $5.5 million, up 16.38% from the prior year.
• Long-Term Deferred Tax improved to $29.1 million in Q2 2026 per BVS's latest filing, from $5.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $29.1 million in Q2 2026 and bottomed at $4.7 million in Q4 2024.
• Historically, Long-Term Deferred Tax has averaged $8.2 million across 3 years, with a median of $5.5 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Long-Term Deferred Tax tumbled 35.84% in 2025, then soared 512.27% in 2026.
• Over 3 years, Long-Term Deferred Tax stood at $4.7 million in 2024, then grew by 16.38% to $5.5 million in 2025, then surged by 426.11% to $29.1 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $29.1 million, $5.5 million, and $5.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.